Sacituzumab Govitecan Reduces Risk of Disease Progression in HR+/HER2- Metastatic Breast Cancer
June 4th 2022A 34% reduction in the risk of disease progression was observed with sacituzumab govitecan vs standard chemotherapy as treatment of patients with hormone-receptor-positive and HER2-negative metastatic breast cancer.
Read More
Hyper-CVAD With Blinatumomab and Inotuzumab Shows High Efficacy in Ph-Negative B-Cell ALL
June 4th 2022The probability of minimal residual disease negativity and complete remission in patients who received hyper-CVAD with blinatumomab and inotuzumab is higher compared with hyper-CVAD and blinatumomab alone.
Read More
Adjuvant Everolimus Reduces Risk of Recurrence or Death in High-Risk RCC
June 4th 2022Results from the phase 3 EVEREST trial presented during the 2022 ASCO Annual Meeting reveal the relapse-free survival advantage of using adjuvant everolimus over placebo in patient with high-risk renal cell carcinoma.
Read More
Six-Year Survival Extends With Brentuximab Vedotin Plus Chemotherapy in Hodgkin Lymphoma
June 4th 2022Therapy with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, in patients with previously untreated stage III/IV classical Hodgkin lymphoma.
Read More
Pembrolizumab With Ramucirumab Boosts Survival Vs SOC in ICI-Resistant NSCLC
June 3rd 2022The use of pembrolizumab plus ramucirumab to treat non–small cell lung cancer in immune checkpoint inhibitor resistant patients showed better overall survival versus standard of care regimens in the Lung-MAP nonmatched phase 2 substudy S1800A.
Read More
Nimotuzumab Plus Chemotherapy Extends OS in KRAS Wild-Type Advanced Pancreatic Cancer
June 3rd 2022The combination of nimotuzumab and gemcitabine extended overall survival in patients with KRAS wild-type advanced pancreatic cancer, especially in those who did not need surgery for obstruction of a pancreatic bile duct
Read More
Hispanic Pediatric Patient With Neuroblastoma Show Worse Overall Survival
May 27th 2022After identifying a survival disparity among non-White Hispanic patients with pediatric neuroblastoma, investigators will next examine the interaction of survival and race, ethnicity, and poverty, acknowledging the intersectionality of these factors due to structural racism in the United States.
Read More
Updated Results Show Encouraging Early Signs for Regorafenib Plus Pembrolizumab in advanced HCC
June 10th 2021An updated analysis, presented at the 2021 ASCO Annual Meeting, showed encouraging signs for the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
Read More
Belzutifan Shows Strong Responses in RCC and Other VHL-Associated Lesions
June 9th 2021Updated findings for belzutifan showed that with further follow-up, the hypoxia-inducible factor-2 alpha inhibitor continues to show significant clinical activity in patients with Von-Hippel Lindau–associated renal cell carcinoma treated in the frontline setting. Updated results from the phase 2 study.
Read More
Pembrolizumab Plus Cabozantinib Achieves High Response Rate in Metastatic RCC
June 9th 2021More the half of patients with metastatic renal cell carcinoma who received pembrolizumab in combination with cabozantinib had a response to the combination at the recommended phase 2 dose and tolerated treatment well.
Read More
Efficacy Improved with Lenvatinib/Pembrolizumab Combo Over Sunitinib Across RCC Risk Groups
June 9th 2021Efficacy was improved with Lenvatinib plus pembrolizumab for patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups over sunitinib.
Read More
Second-line treatment with cetuximab in patients with metastatic colorectal cancer given after irinotecan or oxaliplatin-based regimen failure, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.
Read More
Abiraterone Added to ADT and Docetaxel Prolongs PFS in De Novo mCSPC
June 9th 2021In men with de novo metastatic castration-sensitive prostate cancer treated in the phase 3 PEACE-1 study, the addition of abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved radiographic progression-free surviva.
Read More
Durable Responses Seen with Cilta-Cel at 18 Months in Relapsed/Refractory Multiple Myeloma
June 8th 2021Sustained efficacy and durable responses was seen with Ciltacabtagene autoleucel, an investigational B-cell maturation antigen-directed CAR T-cell therapy, in heavily pretreated patients with relapsed/refractory multiple myeloma.
Read More
In R/R B-NHL, High Marks Achieved by C-CAR066
June 8th 2021A favorable safety profile and promising efficacy was seen with C-CAR066, a novel 2nd generation chimeric antigen receptor T-cell therapy targeting the CD20 antigen, in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.
Read More